Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022-Reference-Cited by-同舟云学术

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Published:2023-01 Issue:1 Volume:34 Page:48-60
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Araujo D.,Greystoke A.,Bates S.,Bayle A.,Calvo E.,Castelo-Branco L.,de Bono J.,Drilon A.,Garralda E.,Ivy P.,Kholmanskikh O.,Melero I.,Pentheroudakis G.,Petrie J.,Plummer R.,Ponce S.,Postel-Vinay S.,Siu L.,Spreafico A.,Stathis A.,Steeghs N.,Yap C.,Yap T.A.,Ratain M.,Seymour L.

Funder

European Society for Medical Oncology

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference64 articles.

1. Design and conduct of early clinical studies of immunotherapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT);Smoragiewicz;Clin Cancer Res,2020

2. Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies;Seymour;Eur J Cancer,2013

3. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT);Booth;Eur J Cancer,2008

4. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT);Booth;Eur J Cancer,2008

5. Targeted agents: how to select the winners in preclinical and early clinical studies?;Goodwin;Eur J Cancer,2012

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations;ESMO Open;2024-08

2. Three steps toward dose optimization for oncology dose finding;Contemporary Clinical Trials Communications;2024-08

3. Dose selection of novel anticancer drugs: exposing the gap between selected and required doses;The Lancet Oncology;2024-08

4. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development;Annals of Oncology;2024-08

5. Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designs;Research Involvement and Engagement;2024-06-19